The developments in molecular imaging over the past two decades have revolutionized the field of biological imaging, with ongoing profound effects on research in life sciences. Subcellular structures and dynamic biologi cal processes that were once optically indistinguishable from one another can now be visualized in great detail using fluorescence imaging against a background of com plex cellular structures and homeo static mech anisms, with a spatial and temporal resolution far superior to that obtained with conventional ima ging modalities 1, 2 . This approach is also poised to transform surgery.
. This approach is also poised to transform surgery.
Over the past few years, research efforts to develop targeted fluorophores for cancer imaging, coupled with the emergence of improved devices for fluorescence detection are set to revolutionize the field of oncologi cal surgery. Surgery remains the cornerstone of treatment for solid tumours, but surgical techniques have not sub stantially changed over the past century. Surgeons rely on subjective assessments during resection (for example, of subtle tactile and visual tissue differences) to distinguish cancer tissues from the adjacent tissues intraoperatively, potentially resulting in either subtotal tumour resection or unwarranted removal of noncancerous tissue 3, 4 . The presence of residual tumour tissue (defined as 'positive margins') after surgery has been reported in up to 30% of radical prostatectomies 5, 6 , 40% of pancreaticoduodenec tomies 7 , and 65% of highgrade glioma resections (in studies carried out in North America and Europe), high lighting the need for better intraoperative detection of malignant tissues 8, 9 . While positive margins are associated with increased rates of local recurrence and worse clini cal outcomes compared with complete resection 6, 8, [10] [11] [12] [13] [14] , overzealous resection can remove or compromise adja cent vital tissue and organs, resulting in poor functional outcomes. With the use of fluorescence guided surgery (FGS), malignancies that once evaded easy detection can be illuminated in realtime in the operating room. Robust detection of cancer tissue, directed by sensitive and specific tumour biomarkers, will eliminate reliance on nonspecific visual cues and tactile differences to dis tinguish malignant from benign tissues. Importantly, this diagnostic imaging modality could be used directly 3-5,8 ‡ , John S. Kuo 2,8 ‡ and Jamey P. Weichert 1,5,8 ‡ Abstract | Over the past two decades, synergistic innovations in imaging technology have resulted in a revolution in which a range of biomedical applications are now benefiting from fluorescence imaging. Specifically, advances in fluorophore chemistry and imaging hardware, and the identification of targetable biomarkers have now positioned intraoperative fluorescence as a highly specific real-time detection modality for surgeons in oncology. In particular, the deeper tissue penetration and limited autofluorescence of near-infrared (NIR) fluorescence imaging improves the translational potential of this modality over visible-light fluorescence imaging. Rapid developments in fluorophores with improved characteristics, detection instrumentation, and targeting strategies led to the clinical testing in the early 2010s of the first targeted NIR fluorophores for intraoperative cancer detection. The foundations for the advances that underline this technology continue to be nurtured by the multidisciplinary collaboration of chemists, biologists, engineers, and clinicians. In this Review, we highlight the latest developments in NIR fluorophores, cancer-targeting strategies, and detection instrumentation for intraoperative cancer detection, and consider the unique challenges associated with their effective application in clinical settings.
as a therapeutic aid for improving resection outcomes and thus, overall survival rates. Such an approach could also simultaneously decrease the rates of surgeryrelated comorbidities, and improve functional outcomes by avoiding critical structures and preventing the need for repeated surgeries, and by reducing operating times and patient exposure to anaesthesia.
Fluorescenceguided imaging requires the adminis tration of a cancerselective exogenous fluorophore and imaging at the optimal timepoint to achieve the best signal tonoise contrast. Fluorophores with excitation and emission spectra in the nearinfrared (NIR) wave length range (700-900 nm) have attracted the most attention owing to their improved depthpenetration range compared with fluorophores that emit electro magnetic radiation of shorter wavelengths. In vivo, background fluorescence and scattering from water and chromophores are minimized in the NIR wavelength range 15, 16 (FIG. 1) . Cancertargeted fluorophores have been widely explored in preclinical models, but only in the past 3 years have they been tested in clinical settings, with cetuximab800CW being one of the first targeted NIR fluorophore to reach clinical trials 17 . The commer cial development of these agents for clinical applica tion has synergized with concurrent improvements in detection instrumentation and software.
Fluorescence imaging exhibits several favourable characteristics that are conducive for clinical trans lation, which include an excellent safety record with clinicallyused probes [18] [19] [20] , a lack of ionizing radiation exposure, realtime detection capabilities with an ade quate field of visualization (FOV), lower costs and much less cumbersome detection instrumentation compared with other intraoperative imaging modalities, and also provide a high sensitivity of detection 1, [21] [22] [23] . Importantly, the ability to couple NIR fluorophores to target mol ecules in order to tailor fluorescence imaging for spe cific purposes enables the application of this modality to numerous clinical indications, especially in the field of oncology in which targetable biomarkers are now being characterized and validated in many cancer types 24 . Other imaging modalities, such as intraopera tive CT and MRI, are not performed with targeted contrast agents as easily as NIRbased imaging because lesssensitive contrast agents are used 25 . In addition, introduction of expensive and bulky CT and/or MRI instrumentation in the surgical suite could also disrupt the surgical workflow.
For many decades, fluorescence has been used for the noninvasive detection of several physiological abnor malities. Fluorescein has been used since the 1960s for the diagnosis of various ophthalmic pathologies 26, 27 . Vascular imaging with indocyanine green (ICG) has proven to be a costeffective imaging modality in assessing perfusion of skin flaps after mastectomy 2, 28, 29 . Fluorophores have also been used for the detection of cancer, but only a small subset of tumour types can be detected using clinically approved nontargeted fluorophores 9, 30 . Attaching fluorophores to targeting agents will ena ble the expansion of fluorescence imaging in clinical settings, and will improve the sensitivity and specifi city of detection. The combination of improved NIR fluorophores with targetable cancer biomarkers has contributed to a surge of interest in fluorescenceguided surgery, evidenced by the introduction of NIR cancer targeted fluorophores in clinical trials for the first time in the early 2010s (NCT01508572, NCT01987375). The cancer targeted fluorophores used in clinical trials contain different fluorophores and leverage a spectrum of targeting strategies, including antibodies, small pep tides, small molecules, activatable fluorophores, and multimodality fluorophores [31] [32] [33] [34] [35] . Herein, we discuss the latest advances in the development of fluorophores and instrumentation for performing FGS in the NIR range, with a particular focus on the cancertargeting strategies used and the regulatory challenges associated with the clinical adoption of this technique.
Approved fluorophores for cancer imaging Indocyanine green. ICG is a heptamethine cya nine fluoro phore, and is the first and only clinically approved fluorophore that displays NIR fluorescence 15 . The commercially available instrumentation used for ICG detection is adjusted for the characteristics that ICG displays in plasma (peak excitation wavelength of 807 nm, and peak emission wavelength of 822 nm) bound to proteins in plasma, which confines ICG to the intravascular space and makes it especially suited for angiography applications 38, 39 . ICGbased angiography and lymphography have been used in a variety of clini cal indications, such as perfusionbased imaging of the liver and blood vessels of the eye, and assessment of lymphatic vessel drainage 2, 28 . Identification of sentinel lymph nodes (SLN map ping), and pathological assessment of lymphnode metastases offers important prognostic information for patients with breast cancer or melanoma 40 . To date, visible dye and radioscintography have been used for SLN mapping 40 . These two techniques are comple mentary -radionuclides provide information on the regional localization of primary lymph nodes, but the poor spatial resolution and the shinethrough effect of radioscintography limits precise intraoperative map ping of SLNs, which can be achieved with optical ima ging 21, 40 . In the past few years, studies on SLN mapping have demonstrated enhanced detection sensitivity and specificity of ICG compared with blue dye and radio scintograpy [41] [42] [43] [44] . The combined use of radioscintography and ICG has attracted interest because it enables pre operative planning before performing intraoperative biopsy [45] [46] [47] [48] . ICG has also been used for intraoperative identifi cation of liver metastases 49 and hepatocellular carci nomas [50] [51] [52] owing to the hydrophobicity and natural clearance of this fluorophore via the hepatobiliary sys tem. In addition, because of having high plasma protein binding properties, ICG can extravasate passively into tumour tissues, which typically have a leaky vasculature and impaired lymphatic drainage 53 . This phenomenon, called the 'enhanced permeability and retention' (EPR) effect, has been used to nonspecifically detect cancers, including ovarian cancer and metastases 53 , pancreatic cancer 54 or peritoneal metastases 55 , among others. The use of passive targeting mechanisms, however, might not be ideal for specific detection, owing to reliance on lowcontrast and nonspecific signals (for example, related to inflammation).
5-aminolevulinic acid. 5aminolevulinic acid (5ALA) is an amino acid currently approved in Europe, Canada, and Japan for use in FGS of glioblastoma based on the results of a phase III clinical trial 9 . In cells with high meta bolic activity, 5ALA is processed via the haemesynthesis pathway to produce abundant protoporphyrin IX, which exhibits a fluorescence absorption peak of 405 nm, and an emission peak in the red visible light range (635 nm), permitting fluorescence imaging on the surface of tissues and in a depthrange of millimetres 56 . In addition, por phyrins have photodynamic properties and can generate triplet oxygen species when excited by light of appropri ate wavelength (405 nm) 57 . These properties have been applied in the intraoperative treatment of cancers and premalignant lesions 9, [57] [58] [59] . Studies have demonstrated that patients with gross total resections of both lowgrade and highgrade glio mas have improved survival rates when compared with patients with subtotal resections 8, 13, 14 . In a European phase III clinical trial performed by Stummer et al. 9 , patients who underwent FGS with 20 mg/kg bodyweight of 5ALA (n = 161) had significantly improved total resection (65% versus 36%; P <0.0001) and 6month progressionfree survival (41% versus 21%; P = 0.0003) rates than patients who underwent conventional micro surgery under white light (n = 161). The initial success with 5ALA has spawned the initiation of clinical trials at academic centres outside Europe for fluorescent detection of gliomas (NCT01502280, NCT02119338, NCT02050243, NCT02191488).
5ALA has also been used in clinical settings for the photodynamic detection and photodynamic therapy of many superficial skin lesions, and its use is being investi gated in several cancer types [59] [60] [61] [62] [63] [64] [65] . 5ALA is a small lipo philic zwitterion, and therefore the cellular penetration into lesions thicker than 2 mm decreases treatment effi cacy 61, [66] [67] [68] . In addition, the low tissue penetration of the protoporphyrin IX excitation and emission wavelengths limits the effectiveness of photodynamic therapy 61, 66 .
Methylene blue. Methylene blue is a clinically approved dye with visible and NIR fluorescent properties, and a unique biodistribution profile that has been exploited for cancer imaging. Methylene blue is commonly used as a blue dye in conjunction with radiocolloids to identify SLNs in patients with melanoma or breast cancer 28, 40, 47 . This agent exists in the form of several cations in solution and displays farred fluorescence at low concentrations, with a peak emission wavelength of 688 nm 67, 68 . The unique biodistribution and fluores cence properties of methylene blue have been exploited by several investigators to identify vital structures, including the ureters 69 and the parathyroid gland (NCT02089542, NCT01598727), as well as cancers such as neuro endocrine insulinomas 74 , fibrous pan creatic tumours 75 , paragangliomas 30 , and para thyroid adenomas 72 , albeit in small case studies; however, the tumour targeting properties of methylene blue remain poorly understood. Methylene blue also exhib its photodynamic properties, with a high efficiency of generating triplet oxygen species when excited by light 76 . Photodynamic treatment of bloodborne infec tions 71, 77, 78 (NCT00917202), and sepsis (NCT01797978) with methylene blue has been reported.
Fluorophore development
Although ICG, 5ALA, and methylene blue have been investigated in nontargeted applications 2 , their use in oncological imaging has been limited by several key factors, including the lack of specific cancertargeting and conjugation potential of ICG, the limited know ledge of the tumourtargeting potential of methylene blue, and the poor tissue penetration and imaging depth properties of 5ALA. Thus, research efforts of the past decade have focused on developing new NIR fluoro phores with improved tissuedepth penetration, and then transforming them into cancerselective fluoro phores. Remarkable improvements in the photophysical and photostability properties of organic fluorophores have made them suitable for in vivo applications; these organic fluorophores now display fluorescence in the NIR window (700-900 nm). Properties such as tissue absorbance, autofluorescence, and light scattering are improved in this range compared with the visible light range, and thus, signaltonoise ratio (SNR) and depth of detection (up to 1 cm) are enhanced 15, 79, 80 (FIG. 1) .
Substantial absorbance is detected below this window, by chromophores and water.
To be used in vivo, fluorophores should demonstrate fluorescence in the NIR window, and should also have good solubility, photophysical characteristics (bright ness, and peak excitation and emission wavelengths (Stokes shift), and photostability. Owing to their hydro phobicity, fluorophores often demonstrate poor solu bility and aggregation in solution, which can lead to changes in their excitation and emission ranges, as well as quenching of fluorescence 38, 39 . Fluorophores should also demonstrate optimal photophysical characteristics, including brightness; molar absorptivity (ε), a product of how well they absorb excitation photons; and fluores cence quantum yield (Φ), which indicates how often that absorbance leads to emission of fluorescence. Moreover, their Stokes shift should be sufficient (>30 nm) to ena ble ease of detection, otherwise light contamination and decreased sensitivity can pose concern. Photostability is a general term that describes the retention of the photo physical properties in different chemical environments; to enable accurate assessment, fluorophores should demonstrate photostability in vivo, especially consid ering that detection cameras have different sensitivities at different wavelength ranges. Common photostability concerns with fluorophores include photobleaching, changes in the photophysical characteristics in different media, and changes in photophysical characteristics after plasmaproteinbinding or conjugation to a targeting ligand 81, 82 . Lastly, conjugatable fluorophores should be available for targeted probe development. • Φ: 9.3% In FBS
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Cyanine fluorophores. Cyanine fluorophores have remained the most popular fluorophores for conju gation with targeted ligands owing to their favourable safety profiles, tunable fluorescence characteristics, good solubility, and the commercial availability of con jugates 81 . ICG and IRDye® 800CW (IR800CW; LiCOR Lincoln, Nebraska, USA) are cyanine fluorophores that have undergone safety testing by the FDA. Indeed, ICG has an excellent safety record in clinical settings 18, 20 . IR800CW has undergone a microdosing study meeting the requirements for an FDA exploratory Investigational New Drug study (IND, also referred to as phase 0), with ICG used as control 19 . These molecules represent two of the most commercially developed fluorophores and, currently, IR800CW conjugates are among the first tar geted probes to be tested in several clinical trials for NIR imaging (TABLE 2) .
Cyanines contain two aromatic nitrogen containing heterocyclic ring systems linked by a polymethine bridge. Extension of the polymethine bridge increases the wavelength of emission and excitation, with tri methine (Cy3) and pentamethine (Cy5) fluorophores displaying fluor escence in the visible and farred range, respectively, and heptamethine (Cy7) fluorophores dis playing fluorescence in the NIR range 83 . ICG was the first NIR fluorophore approved for imaging, but the suit ability of this agent is limited because of its low fluor escence quantum yield 84 , lack of conjugation potential 19 , and poor in vivo photostability owing to plasmaprotein binding, photobleaching and aggregation 39, 85, 86 . Many improvements in the optical properties of cyanine derivatives have been made since ICG was first developed. The introduction of a rigid cyclohexyl moiety in the middle of the polymethine bridge, of electron donating groups on the Nsubstituent of the 3Hindolenine, and of a central chlorine atom on the cyclohexyl moiety have substantially improved the photo stability and decreased aggregation of these agents 87, 88 . The addition of sulfonic acid or carboxylic acid groups enhances the solubility, fluorescence intensity, and Stokes shift of these fluorophores 89 ; IR800CW is a novel cya nine fluorophore exhibiting these improved character istics 19 . Choi et al. 90 developed ZW8001, a zwitter ionic cyanine fluorophore with a net neutral surface charge, which displayed low plasma protein binding affinity, improved in vivo photostability, decreased nonspecific uptake, as well as favourable pharmacokinetic (PK) and biodistribution characteristics 37, 90 .
Other fluorophores. Other fluorophore classes are less welldeveloped than cyanine fluorophores, but also display translational potential. In the past decade, efforts have focused on shifting fluorescence profiles to longer wavelengths, that is, from the visible light range to 700-900 nm (NIR I spectrum), and from the NIR I range to 1,000-1,700 nm (NIR II spectrum). Additional efforts to improve the photophysical and photostability characteristics of fluorophores have resulted in the pre clinical development of fluorophores such as squaraines, BODIPY fluorophores, rhodamines, porphyrins, and pthalocyanines that now display fluorescence in the NIR window 81, 83, 91 (TABLE 2) . Common strategies to shift the fluorescence spectra of these compounds have relied on extending the aromatic system and increasing molecu lar rigidity 81, 91 . These modifications, however, are usually accompanied by increased hydrophobicity, which results in poor solubility in water, nonspecific binding, and slow biological clearance 37, 91 . Ongoing efforts are focused on improving the solubility of these fluorophores in order to render them more suitable for in vivo applications.
The encapsulation of these fluorophores can substan tially enhance their solubility, photostability and photo physical characteristics. Conjugation with polyethelene glycol (PEGylation) has been used to increase the solu bility of these hydrophobic fluorophores and improve their PK properties 32, 81, 92 . Antaris et al. 92 described CH0155, the first smallmolecule organic fluorophore with excitation and emission spectra in the NIR II win dow with favourable water solubility and fast biological clearance achieved through PEGylation. When used for imaging, PEGylated fluorophores demonstrated improved spatial resolution in the vasculature and lym phatic system compared with ICG (in the NIR I range) 92 . In addition, PEGylated fluorophores conjugated with a targeting ligand showed a fivefold increase in tumourto background signal compared with an NIR I fluorophore conjugated with the same targeting ligand 92, 93 . LUM015, an activatable fluorophore tested in clinical trials for the detection of softtissue sarcoma and breast cancer also incorporates PEGylation to achieve improved PK prop erties 32 . Thus, the PEGylation of fluorophores represents a way of overcoming their inherent hydrophobicity and poor PK properties while preserving their safety profile in vivo 32, 92, 94 . Other encapsulation methods, such as the use of nano particles, have been used in preclinical studies to deliver fluorophores to animals with cancer, while simultan eously maintaining their photophysical properties and photostability. Fluorophore targeting can involve passive mechanisms, such as EPR, whereby increased vascular permeability and/or decreased drainage of tumour vessels enable large molecules to accumulate within tumour tis sue 53 , or the incorporation of active targeting components on the surface of the nanoparticle. Owing to their pro tective encapsulation, nanoparticleloaded fluorophores display excellent photophysical and photostability prop erties, including bright signals, low aggregation, and even tunable spectral properties 81, 83 . Despite advances in the development of nanoparticleloaded fluorophores, the toxicity of nanoparticles and manufacturing difficulties associated with them have hampered their application in translational studies 81, 83 .
Targeted fluorophore development PK, biodistribution, and dosing. Targeted fluorophore development usually entails the conjugation of fluoro phores to cancertargeting agents through a linker. By using targeted fluorophores, the sensitivity and speci ficity of detection for diseasespecific applications is increased, with favourable SNR profiles 95 . Currently, fluorophores have not been approved by the FDA for intraoperative cancer imaging; however, in the past few The choice of target and fluorophore for a cancer targeting fluorophore can affect its PK and biodistri bution. Sufficient contrast and specificity are achieved when the ligand has a high affinity for a target highly expressed in a particular cancer type, which can be extra cellular (such as receptors or enzymes), or intra cellular (such as intracellular enzymes). Many growthfactor receptors are overexpressed in cancer cells and can be targeted by a variety of ligands, such as antibodies, small antibody fragments, peptides, or even small mol ecules 24 . Antibodies are large (>100 nm), and therefore fluorophore-antibody conjugates exhibit long circula tion times and nonspecific tumour uptake through the EPR effect [96] [97] [98] . Small targeting ligands exhibit faster PK properties, thus achieving sufficient contrast much quicker than large molecules, which enables imaging sooner after administration 99 . On the other hand, small targeting ligands are less amenable to conjugation and chemical modifications than large molecules, and small structural changes can drastically affect their targeting and PK properties 95, 99 . Targeting extracellular enzymes can be a feasi ble approach to design activatable probes with high SNR. Cathepsins and matrix metalloproteinases (MMPs) are extracellular matrix enzymes overexpressed in numerous cancers. In cancer, as well as in inflamma tory conditions, MMPs and cysteine cathepsins alter the microenvironment, facilitating invasion and metas tasis [100] [101] [102] [103] . Proteaseactivated probes generally consist of a quencher conjugated to a fluorophore through a cleavable linker that can be recognized by proteases commonly present at increased levels in the tumour microenvironment, resulting in increased activation of fluorescence, than in nonmalignant tissues. The chal lenges associated with this approach are the diffusion of activatable fluorophores within the tumour micro environment, and decreased specificity, owing to the roles in both cancer and inflammation of the enzymes used in activation [104] [105] [106] . For intracellular targets, the fluorophore-ligand conjugate must enter cancer cells either through passive diffusion or via active uptake of the target (exploiting ligands that specifically bind to cancer cells) 99 . High doses of fluorophore-ligand con jugates that passively diffuse into cancer cells might be required to achieve sufficient contrast 99 . The conjugation of a fluorophore to a targeting ligand might not only affect the photophysical and photo stability properties of the cancertargeted fluorophore, but also its PK and biodistribution properties 79, 95 . As a general rule, the PK and biodistribution of the spatially larger group predominate. Linkers can be incorporated to potentiate interactions between the fluorophore and targeting ligand (which can minimize quenching of the fluorophore), as well as the targeting ligand and the binding site 82 . In addition, cleavable linkers are neces sary for enzymeactivated targeted fluorophores, which are recognized by proteases resulting in the release and activation of the fluorophore at the target site 24, 35, 99 . PK properties affect the optimal imaging time point of targeted fluorophores. Because large ligand fluorophore conjugates (>100 nm) and hydrophobic conjugates bind to plasma proteins and are slowly cleared by the body, delays (hours to days) can occur between administration of the targeted fluorophore and the time of imaging. Targeted fluorophores should be designed with favourable PK properties tailored for their clinical use. An ideal targeted fluorophore should exhibit rapid tumour uptake and prolonged retention of the tar geted fluorophore, as long as the targeted fluorophore is eventually cleared, or is nontoxic 104 . Similarly, the biodistribution properties inform on the usefulness of these targeted fluorophores, because this parameter describes which nonmalignant organs have a role in excretion and nonspecific binding 2, 15, 53 . A combination of high binding affinity for cancer tissue with minimal nonspecific organ binding is ideal, but often not achieved. As the ligand, linker, and fluorophore can affect biodistribution, the individual contribution of each component might be hard to predict and, there fore, new targeted fluorophores should undergo testing in vivo.
Using smaller antibody fragments 98, 107, 108 , employing pretargeting strategies and paired probe methods 25, 109, 110 , and combining activation and targeting strategies 79 can decrease circulation times, increase the specificity of tar geted fluorophores, and lead to morefavourable biodistri bution, thus decreasing potential associated toxicities. The limitations of these strategies and ongoing improvements have been discussed in detail elsewhere 35, 79, 99 . Lastly, another important parameter that influences PK and safety profiles is dosing. Doseescalation studies are designed to determine the maximum tolerated dose and determine if an effective dose is safe 111, 112 . Preclinical studies can help determine the PK profiles and appro priate dosing of targeted fluorophores -scaling up the dose in experiments with other mammalian species and in studies with humans according to body surface area can give a good initial estimate for the appropriate dose 111 . Pilot clinical trials, and phase I and II clinical studies will ultimately determine the appropriate dose and optimal imaging time point for these agents 112 .
Ligand-targeted fluorophores. Conjugation of fluoro phores to cancerspecific ligands increases the sensitivity and specificity for cancer cells that express the receptors for those ligands, enabling the use of low concentrations for fluorescence detection 79, 104 . Cancerspecific ligands tested in clinical trials include antibodies, peptides, and small ligands (TABLE 3) .
After the approval of the antiCD20 monoclonal antibody rituximab in 2006, no less than 15 mono clonal antibodies have been approved for cancer ther apy 113 . Importantly, once approved, these antibodies can be repurposed for diagnostic applications, such as FGS. Bevacizumab800CW, a monoclonal antibody to VEGF, is being evaluated for the diagnosis of a variety of premalignant and malignant conditions, including colorectal cancers 11 (NCT01508572, NCT02583568, NCT02129933, NCT01972373, NCT01691391). Previous studies performed on human colorectal biopsy specimens have identified VEGF as a promis ing target with 79-96% (n = 304) of colorectal lesions expressing VEGFA 114 . More than 95% of head and neck squamouscell carcinomas overexpress EGFR and thus, cetuximab800CW and panitumumab 800CW, both targeting EGFR, are undergoing evalu ation for intra operative detection of these tumours 115, 116 (NCT01987375, NCT02415881 ; FIG. 3 ). huJ591 is a second generation antibody that targets prostate specific membrane antigen (PSMA), which is highly expressed in virtually all prostate cancers 117, 118 . Bander et al. 119 demonstrated in preliminary clinical trials that a radioconjugate form of huJ591 had a sensitiv ity of nearly 100% for the identification of softtissue and bone metastases in patients with prostate cancer; huJ591 is now being conjugated to IR800CW for the intraoperative detection of residual disease in such patients (NCT01173146). Up to 30% of prostatectomies leave residual tumour, and therefore the clinical need to identify residual disease intra operatively remains to be addressed 5, 120 . Other antibody-fluorophore conjugates are in preclinical development, including some featur ing both approved antibodies (daclizumab, trastuzumab, and panitumumab) and the approved fluorophore ICG 82, 94, 121 . Recognized limitations of antibodybased imaging include poor extravasation into the tumour (owing to large molecular size), long circulating half life, and nonspecific uptake through the EPR effect [96] [97] [98] . Ongoing efforts to decrease the circulation times using smaller antibody fragments 98, 107 , and pretargeting strat egies 109, 110 are at the preclinical stage. BLZ100 is an imaging agent composed of a small peptide chlorotoxin, which targets annexin A2, conju gated to functionalized ICG 31 . Annexin A2 overexpression has been exploited to label many solid tumours, includ ing primary brain tumours and other neuroectodermal tumour types, and is now being evaluated clinically in several phase I trials after successful proofofconcept trials in canine cancer models 31, [122] [123] [124] (NCT02496065, NCT02464332, NCT02462629, NCT02234297). A smallpeptide, cyanine fluorophore conjugate, GE137, was developed for endoscopic detection of hyperplastic and malignant polyps that overexpressed MET (also known as hepatocyte growth factor receptor) 125 ,126 . Burggraaf et al. 125 designed a Cy5fluorophore conju gated to a peptide with high affinity for an extracellular epitope of MET that displayed fast PK properties and a favourable safety profile in healthy human volunteers, and performed imaging with a prototype endoscope opti mized for GE137. In a sample cohort with 15 patients harbouring a total of 101 polyps, these agents enabled vis ualization of all neoplastic polyps that were visible under white light, in addition to 9 polyps that were not visible in those conditions 125 . Many cancers, including carcinomas of the breast, lung, and ovary, express high levels of folate recep tor (FR)α 127 . Van Dam et al. 33 performed an initial clinical pilot study with EC17, a conjugate compris ing fluor escein isothiocyanate and the small molecule folate. Sensitive and specific intraoperative detection of FRαpositive ovarian cancer with this targeted conjugate was demonstrated in a study involving 12 patients with ovarian cancer 33 . This agent is being further evaluated in phase I trials in patients with lung, breast 128 , or renal cancers, in which this agent shows promise in detecting metastases owing to a high rate of concordant expres sion of FRα between the primary cancer and metasta ses 129 (NCT01996072, NCT01994369, NCT01778933, NCT01778920, NCT02317705). EC17 is also being evaluated in phase I trials for the detection of primary hyperparathyroidism. OTL38, a folate-Cy7fluorophore conjugate with good depth penetration, is being evalu ated for the intraoperative detection of FRαpositive ovarian cancer (NCT02317705) 99 . In 2015, a comparison of OTL38 and EC17 demonstrated that OTL3 exhibits a 3.3fold higher signaltobackground ratio in mouse flank tumour xenografts, and very minimal autofluores cence compared with EC17, illustrating the advantages of NIR fluorescence over visiblelight fluorescence 34 . We have developed smallmolecule alkylphos phocholine (APC) analogues that display avidity for a wide array of cancers including glioblastoma, breast, and colorectal cancers [130] [131] [132] [133] . These small molecules are selectively taken up in lipid rafts, which are abundant on cancer cells and cancerstem cells, and are subse quently retained in cancer cells owing to a deficiency of catabolic enzymes 130 . CLR1502, a conjugate of the fluorophore IR775 with APC, can potentially be used for intraoperative detection of numerous cancer types in clinical settings [131] [132] [133] (Supplementary information S1 (movie)). CLR1502 demonstrated an impressive SNR in orthotopic mouse models of human glioblastoma, with an average SNR of 9.3 and a twofold greater SNR compared with 5ALAbased imaging 133 . Use of this targeted fluorophore can substantially improve resec tion outcomes in GBM, in which only around 35% of surgeries result in clear margins 8, 9 . Delineation between malignant and benign tissues is especially important in GBMs owing to the vital importance of avoiding damage to adjacent nonmalignant brain tissue, and to the high recurrence rates in these aggressive cancers. Importantly, these APC analogues can be used for multimodality imaging and therapeutic applications because they exploit the same mechanism of uptake and retention as a suite of diagnostic imaging and targetedtherapy analogues (I124CLR1404 and I131CLR1404) cur rently in preclinical and clinical development 130, [134] [135] [136] (NCT01898273, NCT00925275).
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Activatable fluorophores.
Fluorophores can be designed to emit fluorescence only after binding the target tissue, substantially enhancing the SNR by simul taneously decreasing the background and increasing the fluorescent signal activated upon target binding. Strategies in activated fluorophore design utilize photo chemical quenching, ligandtargeted activation, or both 79, 95 . Photochemical quenching methods rely on selfquenching, homofluorescence and heterofluores cence resonance energy transfer, Hdimer formation, and photoninduced electron transfer, which have been discussed in detail elsewhere 95 . The activatable fluorophores that have initially been tested in clinical trials include LUM015 and AVB620, which leverage mechanisms of protease activation that we have already discussed. Whitley et al. 32 evaluated LUM015, the first activatable fluorophore to be tested in clinical trials, in a cohort of 15 patients with soft tissue sarcoma or breast cancer (NCT01626066), after the ini tial success of preclinical studies in dogs and mice 32, 137 . LUM015 is composed of the quencher QSY21 linked to a Cy5 fluorophore and a 20 kDa PEG molecule 32 . Upon cleavage of the linker by cathepsin, the Cy5 fluorophore becomes unquenched and can illuminate tumour mar gins. Initial studies demonstrated that LUM015 is selec tively distributed to tumours, and its activation provides an average tumourtonormaltissue contrast ratio of 4.1 (REF. 32 ). The ratiometric activatable cell penetrating peptide AVB620, developed by the teams of Tsien and Nguyen 105, 106 , is undergoing initial clinical pilot studies in patients with breast cancer (NCT02391194). These activatable cellpenetrating peptides are composed of a polycationic peptide conjugated with Cy5 and Cy7 fluorophores, a cleavable linker, and a polyanionic fragment 115, 116 . Upon cleavage of the linker by MMP2 and/or MMP9, the polycationic peptide and attached fluorescent cargo can penetrate into tumour cells and lymphnode metastases. Initially, the Cy5 fluorophore is quenched owing to the close proximity to Cy7 but, upon cleavage, the Cy5 signal to Cy7 signal ratio increases over 40fold 106 . The use of ratiometric ima ging circumvents the problems associated with quanti fication using singlewavelength intensity measurements (dose dependent uptake and PK characteristics), and the fluorophore exhibits fast activation (within 2 h) 106, 138, 139 . Other fluorophores used preclinically, but with strong translational potential are in development. Urano, Kobayashi and colleagues 104 synthesized and tested γglutamyl hydroxymethyl rhodamine green (γGluHMRG) with intramolecular spirocyclic caging that resulted in complete quenching. Glutamate cleav age with γglutamyltranspeptidase (GGT), which is not expressed in normal tissue, but is overexpressed on the cell membrane of various cancer cells, including cervi cal and ovarian cancers, leads to the complete uncaging and unquenching of the fluorophore. In mouse models of disseminated human peritoneal ovarian cancer, acti vation of γGluHMRG occurred within minutes of sprayon application 104 . Nevertheless, problems associ ated with diffusion of such activatable fluorophores and nonspecific activation in an inflammatory milieu might decrease the specificity of detection 35, 102, 103 . In other studies, pHactivatable fluorophores, such as pH activatable BODIPY 140 and cyanine fluorophores 141 , have been used to visualize tumours.
Combination of activating and targeting strategies is currently being pursued in order to increase the specific ity of activation 95 . In a preclinical study, ICG was conju gated to clinically approved monoclonal antibodies (such as daclizumab, trastuzumab, and panitumumab), which quenched fluorescence through purported hydrophobic interactions between the fluorophore and antibody 82 ; however, fluorescence was unquenched upon tumour uptake and dissociation of ICG from the antibody. The adoption of antibody-ICG conjugates in clinical settings might prove easier than that of other fluorophorerelated compounds because both the fluorophore and the tar geting antibodies are currently approved for clinical use, and clinical imaging devices optimized for ICG are read ily available. Importantly, these conjugates display excel lent signaltobackground ratios owing to the combined effect of targeting and activation.
Inherent-targeting naked fluorophores. Several fluoro phores have been developed to have the inherent ability of targeting tumours. For example,Tan et al. 140 demon strated cancerselective uptake of the heptamethine cya nine fluorophore IR780 in multiple rodent xeno graft models of cancer and in a chemicallyinduced lung cancer model. Other Cy7 fluorophores, such as IR783 and MH148, also target multiple cancer cell lines; IR783 demonstrated good in vivo tumour uptake in rodentflank xenograft models of human prostate, blad der, pancreatic, and renal cancers 141, 142 . Tumour uptake and tumoricidal activities have also been described for . The accu mulation of lipophilic charged infrared fluorophores in tumours can be facilitated using organic cation trans porter proteins, and organic anion transporter proteins (OATPs) owing to the high mitochondrial membrane potentials detected in malignant cells 143, 147 . In 2014, Wu and collaborators 148 (NCT02464332) demonstrated that hypoxia upregulates the expression of OATPs, resulting in in vivo uptake of MH148 and average SNR values of 9.1. The ability of these fluorophores to target cancer might represent a feasible method leveraging small molecules, which might have the advantages of simpli city and low costs. The uptake of such small molecules might be further optimized through additional studies of structure-activity relationships.
ICG and methylene blue have both demon strated structureinherent targeting activity towards many cancer types and nonmalignant organs, pos sibly owing to OATPmediated transport and to the EPR effect 30, 49, 72, 75, 149, 150 . Many new fluorophores with structure inherent targeting potential for other tissues are under development (for example, fluorophores that illuminate nerves 151, 152 , and the parathyroid and thy roid glands 153 ); such fluorophores could prove useful in delineating vital organs and structures during surgery. As the detection technology and the arsenal of available fluorophores with different spectral properties continue to grow, multispectral imaging -that enables imaging of multiple organs of interest with cocktails of targeting fluorophores -will become a possibility 79 . Hyun et al. 153 have demonstrated proofofconcept of multispectral imaging to distinguish the thyroid gland from the para thyroid gland during surgery using a cocktail of two targeted fluorophores and a dualchannel NIR imaging system. In addition, paired probe methods -using a targeted fluorophore and an untargeted fluorophore with different spectral properties -might help resolve the issue of nonspecific targeting 154 .
Multimodality fluorophores.
Each imaging modality has unique strengths and limitations and thus, combining multiple imaging modalities is a strategy to overcome the limitations of single modalities by synergizing the bene fits of both modalities. Low depth of penetration and lack of robust quantification limit fluor escence detec tion, even in the NIR range. Combining fluorophores with radioactive tracers would integrate the advantages of quantitative detection and the unlimi ted depth of detection of radioactive tracers, and the high spatial resolution and functional molecular imaging poten tial of targeted fluorophores that are ideal for in vivo applications. SLN mapping using such a dual modality approach has been initiated in human clinical trials for preoperative detection and intra operative illumination of many solid tumours 155 . The first clinical trial with a tar geted multi modality single photon emission computed tomography (SPECT)/fluorophore imaging is under way 156 : indium111DOTAgirentuximab-IR 800CW is being evaluated as a duallabelled agent for image guided surgery (NCT024975599); girentuximab is a monoclonal antibody to carbonic anhydrase 9, which is expressed in 95% of renalcell carcinomas 157 . Thus, the use of this agent might bridge preoperative detection and intra operative fluorescence detection of renalcell carcinomas. In addition to preoperative sta ging and localization, the use of theranostic radio tracers can help characterize the PK properties, dosing, and quantifica tion of their fluor escent counterparts; which otherwise might be difficult and invasive owing to the limited depth penetration of fluorescence.
The development of dualmodality probes with radiot racer and fluorescence modalities, and cocktails of theranostic companions can facilitate the clinical testing of fluorescent probes; however, the FDA does not permit testing two agents in a single clinical trial design and thus, the use of theranostic probes to facilitate the translation of fluorescent counterparts in the clinical setting will require the development of innovative strategies, new guidelines, or prior approval of theranostic radiolabelled probes. Indeed, many radioactive probes for cancer detection are currently under preclinical and clinical development, which holds promise for the use of thera nostic radiotracers in conjunction with their fluorescent counterparts 119, 121, 158, 159 (NCT01691391, NCT01894451).
Barriers to clinical adoption
Targeted fluorophores have the potential to change the way oncological surgeries are performed. Realtime sensitive and specific detection of cancer intraopera tively has the potential to improve survival outcomes for patients, as well as decrease the rate of comorbidities associated with prolonged exposure to anesthesia, repeat surgeries, and removal of normal functional tissues. For FGS to bear promise, however, several application, regu latory, and clinical challenges remain; some are charac teristic of any new technology, whereas others are unique to fluorescence technologies. Herein, we outline the major challenges that currently impede the clinical adoption of FGS.
Application challenges. The detection of NIR fluoro phores is constrained by the compatibility of the optimal detection instrumentation with the currently used surgi cal tools and setup of the operating room. Importantly, the surgical workflow should be minimally affected to facilitate the adoption of this technology. Integration of the detection instrumentation with surgical tools has led to the development of a variety of devices for openfield surgery 33, [160] [161] [162] , endoscopes 23, 163 , and laparoscopes 164, 165 for intraoperative NIR fluorescence visualization (TABLE 4) . In addition to integrating camera systems, many of these devices superimpose the fluorescence image onto the surgical FOV to prevent alternating between two FOVs. Special lighting conditions are also necessary in the operating room: during fluorescence visualization with both ICG and 5ALA, the lighting must be dimmed or switched off to prevent light contamination 166, 167 . To cir cumvent this problem, transient lighting approaches have been developed to switch from NIR collection to ambient lighting at a frequency sufficiently high enough to avoid disrupting the surgical workflow or markedly decreasing detection efficiency. Switching to lightemit ting diode (LED) technology with NIR reflective films can also substantially decrease interference from NIR 168 . A learningcurve exists for the proper application of any new technology; as FGS becomes widespread, sur geons using this technology might require additional training to use the detection instrumentation and to be knowledgeable about the unique behaviour of targeted fluorophores, in order to ensure a safe and effective use of these agents 169 .
Regulatory challenges. Successful pairing of camera specifications and fluorophore properties achieves the highest sensitivity for the minimal amount of fluoro phore required for FGS. The FDA can require pairing of an optimized detection device to a particular fluoro phore (termed a 'combination product') to approve clinical testing in conditions that facilitate appropriate use and mitigate toxicity 3 (FIG. 4) . Currently, the only clinically approved instruments are optimized for the wavelength profile of ICG, and have not been optimized for the detection of low amounts of the fluorophore 170 . Newly developed fluorophores might have unique excitation and emission profiles that would not be com patible with this clinically approved instrumentation and thus, might need to be paired with a customized detec tion device tailored to their properties; some investi gators have developed custom imaging systems tailored to the excitation and emission spectra of fluorophores they have designed 32, 171 . Pairing devices to specific fluorophores, however, might be a restrictive approach that would impede the clinical adoption of FGS 1, 3, 21 . An alternative to individual fluorophoredevice pairings would be to pair fluorophores with devices according to wavelength overlap 170 . In the USA, traditional drugdevelopment path ways can be expensive and timeconsuming. To date, ICG and IR800CW are the only NIR fluorophores that have undergone safety testing 18, 19 . Exploratory (e)IND studies could facilitate the preclinicaltoclinical trans lation of new targeted fluorophores, such as IR800CW and several novel targeted fluorophores undergoing the same process 19 (NCT01173146, NCT02048150, NCT01778933). eINDs enable early clinical trials (phase 0) to proceed with a limited amount of clinical data (10-15 patients) if the investigational imaging agent is administered at subpharmaceutical doses (≤100 μg of a synthetic drug or ≤30 nmol of a protein) 171 . These studies can help investigators to determine the feasibility of using a targeted fluorophore in a very small number of patients before additional resources are spent on a more traditional IND process. The initial characterization of PK and pharmacodynamic parameters can be done in healthy volunteers, and doseescalation studies designed according to novel modelbased designs or specifically for molecularly targeted agents can be used in order to mitigate potential complications for patients with cancer and to encourage patient enrolment 25, 112, 125 . Other regu latory bodies, such as the European Medicines Agency, have different policies, but encounter similar challenges. At this early stage in FGS development, all the regula tory bodies are learning how to address the regulatory process for targeted fluorophores and devices; whether a fluorophore and companion device with clinical applica bility will be regulated as a drug, device, or combination product remains an open question 3 .
Clinical trial considerations. The agents discussed herein represent the adoption of new strategies for surgical resection -currently, no agreement exists on what the gold standard for clinical trial designs should be in order to demonstrate efficacy and safety of these approaches. Potential primary clinical end points are sensitivity and specificity of detection compared with histological confirmation, recurrence rates, and survival outcomes 34 . Secondary end points might include poten tial reduction in operation durations, associated costs, and rates of repeat surgeries and/or potential complica tions. These end points might need to be specific to the cancer type being evaluated. Moreover, the inability to blind the surgeons to FGS poses an additional challenge in clinical trial design. For multicentre studies, quanti tative standards to compare detection sensitivities of different instruments are also needed.
The surgical approach and technique varies substan tially between disease types and anatomical locations, which in turn influence the potential clinical value of FGS. Careful considerations of cancer types that can be favourably affected using FGS are warranted; not all cancers will benefit from FGS (for example, cancers with very high cure rates). Conversely, minimally inva sive surgical techniques that occur in low ambientlight environments with limited tactile feedback in which the surgeon is operating from a monitor (such as laparo scopic surgery or robotic surgery) are likely to benefit from FGS 3, 4 . In addition, studies in the patient groups most likely to benefit from FGS need to be undertaken. Candidates for FGS should exhibit expression of the targetable biomarkers; however, the heterogeneous expression patterns that exist between patients and even within the same patient can complicate the candidate selec tion process. Histological confirmation or preopera tive staging with theranostic radiotracers might help identify candidates most likely to benefit from FGS 3, 4 . Other challenges to the clinical adoption of FGS are discussed in further detail in a recent consensus report of the first International Society of ImageGuided Surgery meeting 3 .
Conclusions
The in vivo use of NIR fluorophores has garnered increasing attention because of their favourable wave length characteristics and ability to be conjugated to known tumourtargeting agents, enabling intraoper ative cancer detection. Currently, surgeons must rely on nonspecific tactile and visual cues to distinguish tumours from adjacent nonmalignant tissues, and have at their disposal a few fluorophores with limited tumour targeting potential and unfavourable photo physical characteristics. In the past few years, multiple targeted fluorophores have been introduced in clini cal trials; such agents feature targeted fluorophores with improved properties, and novel cancertargeting strategies. With the development of fluorophores with improved physicochemical and tumourtargeting prop erties, and of new detection instrumentation, surgeons could soon achieve sensitive and specific intraoperative cancer detection. This advance could revolutionize the management of patients with cancer by improving the safety of surgical oncology procedures, increas ing the efficiency and effectiveness of discrimination between cancers and vital structures, and decreasing the rates of surgeryrelated morbidities. Survival out comes can be improved by realtime visualization of primary and metastatic tumours at and beyond the margins, which would maximize resection efficiency and improve cancer staging (for example, with SLN mapping). In addition, the combination of fluorescent agents with radiotracers could potential increase the accuracy of cancer staging and improve decisionmak ing on antitumour treatments. These advances could drive a positive move towards reducing the high healthcare costs related to oncology procedures, and improving the quality of cancer care.
Owing to the novelty of realtime fluorescent cancer detection strategies, many implementation barriers remain, including the feasibility of clinical applications, regulatory challenges, and considerations regarding clinical trial design. Thus, multidisciplinary collabora tion between experts will be required to develop, trans late, and realize the full clinical potential of fluorescent cancer detection.
